Literature DB >> 30578311

Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.

José Pérez-Garcia1,2, Javier Cortés1,2,3,4, Otto Metzger Filho5.   

Abstract

BACKGROUND: Data on the efficacy of chemotherapy regimens in patients with advanced invasive lobular carcinoma (ILC) of the breast are limited. We investigated the efficacy of single-agent eribulin for the treatment of advanced ILC when compared with invasive ductal carcinoma (IDC). PATIENTS AND METHODS: Results from the eribulin arms of two phase III studies (305 [EMBRACE] and 301) and a single-arm, phase II study were pooled. The studies involved patients with metastatic breast cancer who had previously received treatment with an anthracycline and a taxane. In all three studies, the dose of eribulin mesylate was 1.4 mg/m2 given on days 1 and 8 of a 21-day cycle. Overall survival (OS), progression-free survival (PFS), and response rates in patients with ILC were assessed and compared with data from patients with IDC.
RESULTS: In total, 1,152 patients were included in this analysis (118 patients with ILC and 1,034 patients with IDC). Median OS was similar in patients with ILC and IDC (13.4 vs. 13.5 months; hazard ratio [HR], 1.10; 95% confidence interval [CI], 0.87-1.38); as was median PFS (4.1 vs. 3.6 months; HR, 0.91; 95% CI, 0.72-1.14). There were no major differences in response rates between the two groups.
CONCLUSION: This retrospective analysis suggests that eribulin demonstrates similar efficacy in patients with ILC and IDC with metastatic disease who have previously received an anthracycline and a taxane. IMPLICATIONS FOR PRACTICE: Data on the efficacy of chemotherapy regimens in patients with advanced invasive lobular carcinoma (ILC) of the breast are limited. This pooled retrospective analysis of three clinical studies demonstrates that the magnitude of benefit of eribulin in the metastatic setting did not differ between patients with ILC versus invasive ductal carcinoma (IDC), even when restricting for patients with estrogen receptor-positive/HER2-negative IDC. © AlphaMed Press 2018.

Entities:  

Keywords:  Chemotherapy; Eribulin; Invasive ductal carcinoma; Invasive lobular carcinoma; Pooled analysis

Year:  2018        PMID： 30578311      PMCID： PMC6693696          DOI： 10.1634/theoncologist.2018-0182

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  18 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Invasive lobular breast cancer: subtypes and outcome.

Authors:  Monica Iorfida; Eugenio Maiorano; Enrico Orvieto; Patrick Maisonneuve; Luca Bottiglieri; Nicole Rotmensz; Emilia Montagna; Silvia Dellapasqua; Paolo Veronesi; Viviana Galimberti; Alberto Luini; Aron Goldhirsch; Marco Colleoni; Giuseppe Viale
Journal:  Breast Cancer Res Treat       Date:  2012-03-08       Impact factor: 4.872

3.  Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Authors:  Javier Cortes; Linda Vahdat; Joanne L Blum; Chris Twelves; Mario Campone; Henri Roché; Thomas Bachelot; Ahmad Awada; Robert Paridaens; Anthony Goncalves; Dale E Shuster; Jantien Wanders; Fang Fang; Renuka Gurnani; Elaine Richmond; Patricia E Cole; Simon Ashworth; Mary Ann Allison
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

4.  Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.

Authors:  Catharina Wenzel; Rupert Bartsch; Dagmar Hussian; Ursula Pluschnig; Gabriela Altorjai; Christoph C Zielinski; Alois Lang; Anton Haid; Raimund Jakesz; Michael Gnant; Guenther G Steger
Journal:  Breast Cancer Res Treat       Date:  2006-10-24       Impact factor: 4.872

5.  Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics.

Authors:  Jing Yu; David J Dabbs; Yongli Shuai; Leo A Niemeier; Rohit Bhargava
Journal:  Am J Clin Pathol       Date:  2011-07       Impact factor: 2.493

6.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Authors:  Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves
Journal:  Lancet       Date:  2011-03-02       Impact factor: 79.321

Review 7.  Lobular breast carcinoma and its variants.

Authors:  Emad A Rakha; Ian O Ellis
Journal:  Semin Diagn Pathol       Date:  2010-02       Impact factor: 3.464

8.  Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.

Authors:  Otto Metzger-Filho; Zhuoxin Sun; Giuseppe Viale; Karen N Price; Diana Crivellari; Raymond D Snyder; Richard D Gelber; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch; Fatima Cardoso
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

9.  Trends in incidence rates of invasive lobular and ductal breast carcinoma.

Authors:  Christopher I Li; Benjamin O Anderson; Janet R Daling; Roger E Moe
Journal:  JAMA       Date:  2003-03-19       Impact factor: 56.272

10.  Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.

Authors:  Otto Metzger-Filho; Marion Procter; Evandro de Azambuja; Brian Leyland-Jones; Richard D Gelber; Mitchell Dowsett; Sherene Loi; Kamal S Saini; David Cameron; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Christian Jackisch; Richard Bell; Christos Sotiriou; Giuseppe Viale; Martine Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544
View more
  2 in total

Review 1.  Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.

Authors:  Jason A Mouabbi; Amy Hassan; Bora Lim; Gabriel N Hortobagyi; Debasish Tripathy; Rachel M Layman
Journal:  Breast Cancer Res Treat       Date:  2022-03-26       Impact factor: 4.872

Review 2.  Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.

Authors:  Amy E McCart Reed; Lauren Kalinowski; Peter T Simpson; Sunil R Lakhani
Journal:  Breast Cancer Res       Date:  2021-01-07       Impact factor: 6.466
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.